

PARTNER Climatic Health	STUDY TYPE Pilot (baseline → active crossover), decentralized
STUDY SNAPSHOT 16 participants · US-based	THERAPEUTIC AREA Respiratory / lung health (consumer wellness)

KEY OUTCOME

Hyfe's CoughMonitor Suite delivered objective cough data that demonstrated a measurable reduction in cough frequency across 12,000+ hours of continuous monitoring and 97.9% median adherence, giving Climatic Health the quantitative evidence their investors and scientific advisors needed to move forward.

12,013

HOURS OF DATA

97.9%

MEDIAN ADHERENCE

16

PARTICIPANTS

4 wks

STUDY DURATION

CHALLENGE

Climatic Health is a US consumer lung health company developing an inhaled dry powder designed to help the lungs clear mucus and particulates more efficiently. Early beta users had reported anecdotal cough reduction, and the team needed to quantify cough to validate that signal with data rigorous enough to convince scientific advisors and investors, and strong enough to justify a larger randomized trial down the line.

The problem: existing cough endpoints relied on patient-reported outcomes like the Leicester Cough Questionnaire, which are subject to recall bias and offer only periodic snapshots.


"We needed a way beyond a patient reported outcome... something quantitative that could measure cough at a baseline period and then through a couple weeks of use."

— Dale Christensen, Co-Founder, Climatic Health

Climatic Health was seeking an objective measurement solution that was validated for accurate measurement of cough, specific for cough, and fast to deploy.

SOLUTION

Hyfe deployed CoughMonitor Suite (CMS) in a fully decentralized suite: 10 wrist-worn cough monitors shipped directly to participants across the US, paired with a real-time dashboard for Climatic Health’s study coordinator to track adherence and export data on demand.



Participants wore the device continuously (day and night, charging at the bedside) producing timestamped cough counts 24 hours a day for the duration of the study. A two-week baseline was followed by two weeks of active product use, allowing within-subject comparison.

What made this deployment distinctive was its simplicity. Devices were shipped directly to participants’ homes, and continuous, objective quantitation of cough flowed back to a real-time dashboard. Privacy was preserved by design, since only cough timestamps ever leave the CoughMonitor watch. Conversations were not recorded, and no audio was ever transmitted. This mattered for a participant population that skewed older (many 80+), but notably no one had privacy concerns during the study.

RESULTS

Across 16 participants, Hyfe’s CoughMonitor Suite captured 12,013 hours of cough data over 545 participant-days, with an average of 36 days of monitoring per person. Median participant adherence reached 97.9%, with 7 of 16 participants achieving 98% or higher and 4 achieving 100%.

Metric	Result
Total cough data captured	12,013 hours
Participant-days of data	545
Average monitoring per participant	36 days
Median participant adherence	97.90%
Participants with ≥98% adherence	7 of 16
Participants with 100% adherence	4 of 16
Average daily wear time	11.1 hours

OPERATIONAL SNAPSHOT

STUDY DURATION 4 weeks (2-week baseline + 2-week active)	DESIGN Decentralized, open label crossover
PARTICIPANTS 16 US-based adults with chronic cough	DEVICES 10 wrist-worn Hyfe cough monitors deployed
TOTAL DATA CAPTURED 12,013 hours across 545 participant-days	MEDIAN ADHERENCE 97.9% (7/16 participants ≥98%; 4 at 100%)
PARALLEL MEASUREMENT Oura Ring for sleep/HRV correlation	TIMELINE First contact → contracted in ~1 week; contracted → live in ~5 weeks

"We came to Hyfe looking for something quantitative that could go beyond patient-reported outcomes, and that's exactly what we got. The data showed our product reduces cough, our advisors and investors saw it and immediately understood the significance, and the team behind it made the whole thing feel easy. It's the kind of evidence that genuinely moves a consumer health company's program forward"

— Annabelle McNeill, Study Coordinator, Climatic Health

WHAT THIS MEANS FOR YOUR STUDY

For sponsors and consumer health companies running early-phase studies, this deployment demonstrates that Hyfe’s CoughMonitor Suite can complement or replace subjective patient-recorded cough endpoints with continuous, objective data, at a scale and speed that fits lean pilot designs, not just large multi-site trials. The same platform that supports Phase II/III pharma studies can rapidly initiate a decentralized study in weeks, with no clinical sites and no patient diaries, while producing data rigorous enough to convince scientific advisors and investment committees.

Climatic Health’s partnership with Hyfe is ongoing as their research program evolves.